Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTX) Declines By 18.4%

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 464,400 shares, a decline of 18.4% from the July 15th total of 569,400 shares. Currently, 3.0% of the company’s shares are sold short. Based on an average daily volume of 377,200 shares, the days-to-cover ratio is currently 1.2 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of BriaCell Therapeutics in a report on Tuesday, June 4th.

Hedge Funds Weigh In On BriaCell Therapeutics

Several institutional investors have recently made changes to their positions in the company. Onyx Bridge Wealth Group LLC raised its stake in BriaCell Therapeutics by 66.7% in the first quarter. Onyx Bridge Wealth Group LLC now owns 50,000 shares of the company’s stock worth $143,000 after buying an additional 20,000 shares in the last quarter. K.J. Harrison & Partners Inc boosted its position in BriaCell Therapeutics by 7.8% during the 1st quarter. K.J. Harrison & Partners Inc now owns 87,044 shares of the company’s stock valued at $249,000 after acquiring an additional 6,329 shares in the last quarter. Finally, National Bank of Canada FI increased its holdings in shares of BriaCell Therapeutics by 200.0% in the 4th quarter. National Bank of Canada FI now owns 7,500 shares of the company’s stock valued at $40,000 after acquiring an additional 5,000 shares during the period. Hedge funds and other institutional investors own 15.42% of the company’s stock.

BriaCell Therapeutics Price Performance

Shares of NASDAQ:BCTX remained flat at $0.56 during trading on Friday. 124,166 shares of the stock were exchanged, compared to its average volume of 204,671. The business’s 50-day simple moving average is $0.93 and its two-hundred day simple moving average is $2.04. BriaCell Therapeutics has a fifty-two week low of $0.52 and a fifty-two week high of $7.59. The company has a market capitalization of $10.23 million, a price-to-earnings ratio of -0.45 and a beta of 1.29.

BriaCell Therapeutics (NASDAQ:BCTX) last released its quarterly earnings data on Friday, June 14th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of ($0.55) by $0.66. On average, sell-side analysts expect that BriaCell Therapeutics will post -1.39 EPS for the current fiscal year.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.